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Abstract
Rare (RVs) and common variants of the RET gene contribute to Hirschsprung disease (HSCR; congenital aganglionosis). While
RET common variants are strongly associated with the commonest manifestation of the disease (males; short-segment
aganglionosis; sporadic), rare coding sequence (CDS) variants are more frequently found in the lesser common and more
severe forms of the disease (females; long/total colonic aganglionosis; familial). Here we present the screening for RVs in
the RET CDS and intron/exon boundaries of 601 Chinese HSCR patients, the largest number of patients ever reported. We
identified 61 different heterozygous RVs (50 novel) distributed among 100 patients (16.64%). Those include 14 silent, 29
missense, 5 nonsense, 4 frame-shifts, and one in-frame amino-acid deletion in the CDS, two splice-site deletions, 4
nucleotide substitutions and a 22-bp deletion in the intron/exon boundaries and 1 single-nucleotide substitution in the 59
untranslated region. Exonic variants were mainly clustered in RET the extracellular domain. RET RVs were more frequent
among patients with the most severe phenotype (24% vs. 15% in short-HSCR). Phasing RVs with the RET HSCR-associated
haplotype suggests that RVs do not underlie the undisputable association of RET common variants with HSCR. None of the
variants were found in 250 Chinese controls.
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Introduction
Hirschsprung’s disease (HSCR) is a developmental disorder
characterized by the absence of ganglion cells in lower digestive
tract. Aganglionosis is attributed to a disorder of the enteric
nervous system (ENS) whereby ganglion cells fail to innervate the
lower gastrointestinal tract during embryonic development. The
disease can be classified according to the length of the
aganglionosis into short segment (S-HSCR; aganglionosis up to
the upper sigmoid colon; 80% of HSCR cases), long segment (L-
HSCR; aganglionosis up to/beyond the splenic flexure), and total
colonic aganglionosis (TCA) forms. HSCR can manifest isolated
or syndromic. There is significant racial variation in the incidence
of the disease, and it is most often found among Asians (2.8/
10,000 live births). HSCR usually presents sporadically (80% of
the cases), and is most frequent in males (M:F=4:1). Familial
HSCR shows a non-Mendelian inheritance pattern [1].
Both rare and common germ-line RET variants play a role in
HSCR. While RET common variants are strongly associated with
the commonest manifestation of the disease (male, S-HSCR and
sporadic forms), rare coding sequence variants (CDS-RV) are
more frequently found in the less common and more severe forms
of the disease (females, L/TCA-HSCR and familial) [2]. These
CDS-RVs have reduced, sex-dependent penetrance and account
for ,50% of the familial and for ,20% of the sporadic cases.
Over 200 RET CDS-RVs (www.hgmd.cf.ac.uk) have been
described in HSCR. These HSCR RET CDS-RVs mainly cause
loss-of function of the RET protein, a tyrosine kinase receptor.
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in hereditary thyroid cancers [3].
Here we present the screening of the RET CDS-RVs in 601
Chinese HSCR patients, the largest number of patients ever
reported.
Results
In this study we report those RET CDS-RVs (including intron/
exon boundaries) that were not found in our controls. The overall
frequency is ,1%. Exception is R114H, which is present in 38
patients (6.32%) but no in controls. R114H is a founder mutation
within Chinese HSCR patients [4].
RET variants identified in 601 Chinese HSCR patients
We identified 61 different heterozygous RVs distributed in
100 HSCR patients (16.64%) (Tables 1 and S4, Tables S1(A)-
S1(B)). These include 14 silent, 29 missense, 5 nonsense, 4 frame-
shifts, and one in-frame amino-acid deletion in the CDS, 3
deletions and 4 nucleotide substitutions in the intron/exon
boundaries and 1 nucleotide substitution in the 59 untranslated-
region (UT).
Five variants (R114H/R313Q/V292M/P841P/R180X) are in
the dbSNP and one (T278N) in both dbSNP and 1000 Genomes
Project. No population/frequency was reported (March/2011).
Excluding R114H, no parental DNA was available to determine
whether those ‘‘database-reported’’ variants identified in our study
had been inherited from unaffected parents or arisen ‘‘de novo’’.
We identified 6 patients with de novo events, 5 with maternally
inherited and 6 with paternally inherited variants. Four patients
harboured 2 CDS-RVs.
Excluding those patients included in the GWAS, whole RET
deletion in patients homozygous for RET SNPs was not evaluated.
Rare variants in other HSCR series
While 50 RVs identified in this study are novel, 6 (R180X/
T278N/R313Q/E480K/Y1062C/M1064T) have been reported
in other HSCR patients (Chinese/other ethnicities) and 2
(R114H/V292M) in individuals with other RET related disorders
(Material S1).
Y1062C and M1064T have been extensively studied [5]. While
Y1062C affects the RET downstream signalling no RET
disruption has been demonstrated for M1064T [6]. This is in
line our bioinformatics prediction (Table S2) whereby Y1062C is
predicted damaging and M1064T benign. The patient reported
here harbouring Y1062C (C16C_Male_L-HSCR) was born to
unaffected parents and had a distant relative affected. C16C also
has V397M in cis. We could not determine whether these variants
are de novo, yet the fact that Y1062C has been reported advocates
for an inherited mutation that segregates with reduced penetrance.
The recurrence of RET CDS-RVs in ethnically different patients
suggest that these events occurred before the European-Asian split.
Knowing whether RET de novo variants recur or, whether an
amino-acid residue is more prone to DNA changes should be
useful in the identification of putative RET mutation hot-spots.
R180 residue (CGA) has repeatedly been altered leading to
different types of mutations (R180X [7]; R180P [8] and R180Q
[9]). The same is true for R114 and T278. Specific RET residues
are inherently more prone to mutations than others.
RET coding sequence rare variants (CDS-RVs) distribution
across the different HSCR subtypes
The distribution of the RET CDS-RVs was analysed across
different HSCR categories. HSCR patients were therefore
stratified according to i) length of the aganglionic segment -
severity of the HSCR phenotype-; ii) presence/absence of
associated anomalies/syndrome; iii) presence/absence of familial
involvement.
Length of the aganglionic segment. When patients were
stratified according to the length of the aganglionic segment, the
highest frequency of CDS-RVs was found among patients with the
most severe forms of the disease (Table S1A). This is in accordance
with our previous report [2]. Likewise, the highest frequency of
CDS-RVs was found among females, and this became more
obvious as the severity of the HSCR phenotype increased (Table 1
and Tables S1A and S1B).
We then investigated whether there was any correlation
between type of RET mutation and severity of the HSCR
phenotype: among the 17 ‘‘mutated’’ patients affected with the
most severe phenotype, 8 (47.07%) had missense changes or in-
frame deletions; 5 (29.41%) had non-sense or frame-shifts; 2
(11.76%) had silent variants and 2 (11.76%) had intronic
substitutions. Among the 59 ‘‘mutated’’ S-HSCR patients, 48
(81.36%) had missense changes; 3 (5.08%) had non-sense or
frame-shifts; 6 (10.17%) had silent changes, and 2 (3.39%) had
variants in the intronic or 59UT regions (Table S3).
Table 1. Distribution of the RET variants across the different HSCR types.
Short Long TCA TIA Undetermined
HSCR patients
(N=601)
(N=382; 63.56%
a;
[42] {15})
(N=48; 7.99%
a;
[4])
(N=22; 3.66%
a;
[3] {1})
(N=1; 0.17%
a;
[1])
(N=148; 24.63%
a;
[1])
Rare variants Rare variants Rare variants Rare variants Rare variants
Yes (9.82%
a) No Yes (1.50%
a) No Yes (1.16%
a) No Yes (0.17%
a) Yes (3.99%
a)N o
Males (N=490;
81.53%)
49 [4] (15.46%
b) 268 [30] {12} 6 (17.65%
b)[ 1] 28 [2] 4 (25.00%
b) 12 [3] {1} 0 20 (16.26%
b) 103
Females (N=111;
18.47%)
10 [2] {1} (15.38%
b) 55 [6] {2} 3 (21.43%
b) 11 [1] 3 (50.00%
b)3 1 [ 1] 4 (16.00%
b) 21[1]
59 [6] {1} (15.45%
c) 323 [36] {14} 9 (18.75%
c)[ 1] 39 [3] 7 (31.82%
c) 15 [3] {1} 1 [1] (100.00%
c) 24 (16.22%
c) 124[1]
N: number of individuals; S: short segment aganglionosis; L: long segment aganglionosis; TCA: total colonic aganglionosis; TIA: total intestinal aganglionosis;
a: % of the total number of patients;
b: % of the total number of patients of the same sex with the same length of aganglionosis;
c: % of the total number of patients with the same length of aganglionosis; []: patients with associated anomalies; {}: patients with Down syndrome.
doi:10.1371/journal.pone.0028986.t001
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RET CDS-RVs of varying degrees of ‘‘pathogenicity’’.
Familial cases. Three of the 4 patients with an affected
distant relative harboured damaging CDS-RVs variants. This is in
accordance with familial cases being enriched with severe
mutations sufficient to lead HSCR [2,10].
Distribution of the coding sequence rare variants (CDS-
RVs) across the RET gene
It is assumed that HSCR RET CDS-RVs are scattered all over
the gene. Yet, some reports indicate that HSCR RET CDS-RVs
tend to cluster in the extracellular domain of the protein [8,11,12].
‘‘Exonic’’ variants (N=55) where in excess in the sequence
encoding the extracellular domain (EC) of the protein. Thirty-six
(65.45%) variants were in the EC; 3 (5.45%) in the trans-
membrane domain and 16 (29.09%) in the intracellular domain
(Table S3).
Exon 5 (cadherin-domain) was the exon with more variants
(N=9) followed by exon 3 (N=7). Similar data have been
reported by others [8] and whether this is related to the high
recombination rates reported for this exon needs further
investigation [2].
The distribution of variants across RET is relevant as the
functional consequences of missense CDS-RVs correlate with their
position in the sequence [5,13,14]. However, after over 200 RET
deleterious variants reported, no correlation could ever be
established which reflects the contribution of other genetic factors
to the disease including that of HSCR-associated RET common
variants/SNPs.
Assessment of the functional effect of the RET variants
Missense CDS-RVs were assessed for their effect in the protein.
Benign missense CDS-RVs, silent and intronic variants, were
scrutinized for interference with i) signature elements that govern
the splicing machinery (exonic/intronic splicing enhancer/silencer
sequences -ESE/ESS-), and ii) RNA stability, structure and folding
(Table S2).
Out of 29 missense variants identified, 10 were predicted
damaging by both Polyphen and SIFT, 16 were predicted
damaging by Polyphen and tolerated by SIFT and 3 tolerated
by both software packages.
Except L465L, all silent variants were predicted to hinder
splicing. Similarly, all benign non-synonymous/missense variants
as well as the ‘‘in-frame’’ deletion G731del were predicted to
interfere with the splicing machinery. Four intronic variants were
predicted to affect splicing by either disrupting the splice sites
(acceptor/AS or Donor/DS) or the branch point (BP). The 59UT
variant did not alter any regulatory site.
As the effect of point mutations may be dependent on
conservation at both DNA and protein levels, we produced
conservation scores for each variation site (Table S2). Seventeen
DNA sites had the maximum score implying that changes on those
sites are not tolerated. At protein level, the most evolutionary
conserved amino-acids are 4 residues with silent changes (de
novoG954G/L651L/P841P/L1077L).
Silent variants with the highest conservation scores at DNA
(Q327Q/L465L/L1077L) and/or amino-acid level (L651L/
P841P/G954G) and non-synonymous/missense that overlapped
with functional RNA structures (F961L/Y1062C) according to the
UCSC Evofold track were evaluated for their impact on RNA
secondary structure/stability. All but Q327Q were found to alter
the wild-type RNA stem loop (Figure S1). The only silent variant
with no predicted ‘‘damaging’’ effect thus far (L465L) was found to
alter such RNA structure.
Bioinformatics prediction indicates that all variants identified
but one (c.-37G.C) potentially affect the RET function in a
quantitative and/or qualitative manner.
RET rare variants are not necessarily on the RET HSCR-risk
haplotype
A common RET-haplotype highly associated with HSCR
comprising a functional variant (rs2435357 C/T; T=HSCR
associated allele) in intron 1 is associated with reduced expression
of RET both in vitro and in vivo [2,15,16,17,18]. The CDS-RVs cis/
trans location with respect to this low-expressing risk-haplotype is
relevant to the effect and/or penetrance of the variant as the
amount of mutated protein synthesized (hence the effect) would
depend on the haplotype where the CDS-RVs resides. The CDS-
RVs cis/trans location could also explain the RET SNPs association
with HSCR by means of synthetic association [19]. Out of the 100
HSCR patients with CDS-RVs unique to HSCR (Table S4), 68
were homozygous for the RET-risk-haplotype (TT), 9 were
homozygous for the wild-type counterpart (CC) and 23 were
heterozygous (CT). Of these 23 heterozygous patients, we were
able to phase their mutation with the haplotype for 15 (Material
S1) [2,17,20]. There is not excess of risk-haplotype among patients
with CDS-RVs when compared to the whole patient group
(x
2=0;p=0.99), indicating that the occurrence of RET CDS-RVs
is independent of the haplotype background. RET CDS-RVs do
not seem to contribute to the strong association of the RET SNPs
with HSCR.
Discussion
This is the largest RET sequencing study of HSCR patients ever
conducted. Its aim is to provide a catalog of the RET coding
sequence rare variants present in Chinese HSCR patients and
assess the distribution of those variants across the different types of
HSCR patients. In line with previous observations [2], we found
that RET CDS-RVs are more frequently found in the less
common and more severe forms of the disease (females, L/TCA-
HSCR and familial). As in many other diseases, one would expect
a correlation between phenotype and location of the causal variant
in the gene and this was not the case. Similarly, the phenotypic
variability observed among patients bearing the same variant
stresses the difficulty in establishing genotype-phenotype correla-
tions. Undoubtedly, other genetic factors affect the penetrance of
RET rare variants and contribute to the phenotypic variability
[10,20].
We used bioinformatics tools to predict the possible implications
of these variants on the gene function. Importantly, all variants
(but one) were predicted to affect the protein function at different
levels. The prediction of missense mutations should perhaps be the
most straight forward, yet, discrepancies between Polyphen and
SIFT seem to be the norm rather than the exception [21]. More
daunting is to assess the predictions provided for silent and/or
regulatory variants. However, bioinformatics claims cannot
categorically be dismissed no fully accepted and this is widely
exemplified in the literature. For instance, 19 genes were found to
have truncating variants in controls in the resequencing of X-
chromosome exons in mental retardation [22]. On the other hand,
silent and/or regulatory RVs are often neglected and these
variations underlie as many as 50 diseases [23]. Functional
validation and/or faithful segregation of variants with the disease
phenotype (which would only be achievable among the scarce
familial cases with fully penetrant variants) are needed to fully
assess the impact of those variants on the phenotype. Thus, in spite
of the ambiguity regarding the potential pathogenicity of many of
RET Mutations in 601 Chinese Hirschsprung Patients
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HSCR we suspect that all RVs found are damaging. With a few
exceptions, the rare RET RVs presented here are unique to
HSCR patients and the existence of some predicted deleterious
variants in the general population (1000 Genome project) only
confirms that additional genetic/environmental factors are in
some instances needed for the disease to occur. As the majority of
causal RET variants described thus far are heterozygous it would
be tempting to speculate that the manifestation of the disease may
be dependent on factors affecting the expression of the RET allele
in which the variant resides. We have phased the rare variants
with the RET risk-haplotype and conclude that the undisputable
association of RET common variants with HSCR is not due to
rare variants that went undetected in our previous GWAS study.
Thus, this indicates that common and rare variants may
contribute to the disease independently although it does not
disregard a possible joint effect as stated above. Exhaustive
functional analysis of these variants would be out of the scope of
this study and although it could back up the bioinformatics
prediction ‘‘in vitro’’ data alone will not ensure casualty. This
study conveys the problematic assessment of the role of rare
variants in disease and emphasises the difficulty in establishing
genotype-phenotype correlations. Yet, providing a mutation
profile for such a large number of patients will eventually help
elucidate the architecture of the disease.
Materials and Methods
The study was approved by the institutional review board of
The University of Hong Kong together with the Hospital
Authority (IRB:UW06-349/T/1374). Blood samples were drawn
from all participants after obtaining informed consent (parental
consent in newborns and children below age 7).
Patients and controls
A total of 601 HSCR patients (Males=490; Females=111;
M:F=4.4:1) recruited throughout Hong Kong and Mainland
China were included in the study. Four patients (C16C/C48C/
HKC2C/HK75C) reported having a distant relative with the
disease, but never parents. Diagnosis was based on histological
examination of either biopsy or surgical resection material for
absence of enteric plexuses. Sixty-seven patients were syndromic
and among those, 16 had Down syndrome (Table 1).
Among the 601 HSCR patients, 430 patients had been
genotyped for 21 RET SNPs across a ,60 kb region of the RET
gene as we previously described [4], 258 had been included in our
previous genome-wide association study (GWAS) on Chinese
HSCR (discovery phase/replication) [20] and 192 in the
International Hirschsprung disease study on the differential
contributions of RET mutations to Hirschsprung disease liability
[2]. The RET rare variants for 86 of the 601 HSCR patients had
been previously reported [12]. As controls, 250 ethnically matched
individuals (Males=160; Females=90) with no diagnosis of
HSCR were included.
Sequencing of the RET coding regions
The RET 21 exons were screened in patients, parents when
available, and controls to avoid the ascertainment bias caused
when only the exons with variants identified in patients are
sequenced in controls as previously described [12].
Bioinformatics analysis
Seattle SEQ annotation version 5.06 and dbSNP-Q were used
for annotation purposes and queries on dbSNP, HapMap and
1000 Genomes project databases. Polyphen and SIFT (Sorting
Intolerant From Tolerant; scores ,0.05=deleterious are consid-
ered deleterious) were used to assess the effect of non-
synonymous/missense changes on the protein. Human Splicing
Finder Version 2.4.1 (default) was used to investigate whether the
nucleotide changes disrupted/created exonic splicing enhancers
(ESEs) or silencers (ESS), or branch or splice-sites [24]. Default
thresholds were used. To assess whether rare silent or missense
variants could affect the secondary structure/stability of the RNA
we used RNAmute. Variants to be submitted to RNAmute were
selected according to 1) their level of conservation at both DNA
and protein level and ii) by consulting/accessing the UCSC
Evofold UCSC track (41way multi-alignment, hg19) [25].
Conservation was inferred from i) genomic base wise conserva-
tion scores calculated using PhyloP from the PHAST package
(28-species multiple alignment) and from ii) the coded amino acid
conservation examined using ConSurf web server. Among
‘‘silent’’ variants, those variants in the most conserved sites were
thought to have potential functional relevance [26,27].
Haplotype reconstruction
In order to phase rare variants present in individuals
heterozygous for the RET risk haplotype (comprising the
functional rs2435357 RET intron 1 SNP), we used the genotypes
of 21 RET SNP which generated for 430 patients in our preceding
studies. The RET rare variants identified were used as a SNP (one
at the time) to re-construct haplotypes comprising the rare allele
using the statistical software package PHASE version 2 as
previously described [2,4,20]. A relation of the 21 SNPs can be
found in the Cornes et al. manuscript [4].
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